Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Less gas, same safety: new anesthesia method cuts drug use in kidney stone surgery

NCT ID NCT07248917

Knowledge-focused Sponsor: Dr. Lutfi Kirdar Kartal Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two ways of giving anesthesia gas (sevoflurane) during kidney stone surgery. One method used a very low gas flow (minimal-flow), the other a slightly higher flow (low-flow). In 62 adults, the minimal-flow approach used less anesthesia drug while keeping patients safely asleep and stable. The findings suggest minimal-flow anesthesia is a safe, cost-saving, and eco-friendly option.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sevoflurane
What this could lead to
If confirmed, minimal-flow anesthesia could become standard practice, reducing drug costs and environmental impact without compromising patient safety.
What could go wrong
This is a small, single-center study with only 62 patients. Results may not apply to other surgeries or patients with health issues. The study does not test long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

62 people

The number who actually took part.

Started

Oct 2024

Finished

Sep 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 to 65 years ASA (American Society of Anesthesiologists) Physical Status I or II Scheduled to undergo elective retrograde intrarenal surgery (RIRS) under general anesthesia Provided written informed consent Able to cooperate with preoperative evaluation procedures Exclusion Criteria: * ASA Physical Status III or higher History of respiratory disease (e.g., asthma, COPD, restrictive lung disease) Known hepatic or renal dysfunction Neurological or psychiatric disorders that may affect BIS monitoring or anesthetic response Known allergy or hypersensitivity to sevoflurane or other volatile anesthetics Pregnancy or breastfeeding Obesity (BMI \> 30 kg/m²) Anticipated difficult airway or history of intubation complications Participation in another clinical trial within the past 30 days

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anesthesia depth monitoring are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Mycobacterium avium complex disease urolithiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anesthesia depth monitoring Anesthetic consumption Inhalational anesthesia Minimal flow anesthesia Retrograde intrarenal surgery (RIRS) Sevoflurane Urolithiasis

Contacts and locations

Locations

  • Kartal Dr. Lütfi Kırdar City Hospital, University of Health Sciences

    Istanbul, 34865, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.